Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics

Journal of Asthma and Allergy

Volumn 4, Issue , 2011, Pages 19-25

  Scichilone, Nicola ^a   Minaldi, Chiara ^a   Santagata, Roberta ^a   Battaglia, Salvatore ^a   Camarda, Gaetana ^a   Bellia, Vincenzo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Allergen; Asthma; Exhaled breath condensate; Immunotherapy; Inflammation; Pollen

Indexed keywords

EID: 85011838327     PISSN: None     EISSN: 11786965     Source Type: Journal    
DOI: 10.2147/JAA.S17784     Document Type: Article

References (32)

1. Global Initiative for Asthma. GINA report. Global strategy for asthma management and prevention. www.ginasthma.org. Accessed December 15, 2008.
2. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–256.
3. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99(4):450–453.
4. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001; 31(9):1392–1397.
5. Bousquet J, Maasch H, Martinot B, et al. Double-blind, placebocontrolled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol. 1988;82(3 Pt 1):439–446.
6. Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol. 1991;87(5):955–964.
7. McCormack PL, Wagstaff AJ. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs. 2006;66(7):931–938.
8. Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001;56(6):498–505.
9. Gawchik SM, Saccar CL. Pollinex Quattro Tree: allergy vaccine. Expert Opin Biol Ther. 2009;9(3):377–382.
10. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol. 2007;119(4): 881–891.
11. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968.
12. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26(3):523–548.
13. Hopkins M, Lees BG, Richardson DG, et al. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL). Allergol Immunopathol (Madr). 2001;29(6):245–254.
14. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun. 2003;71(5):2498–2507.
15. Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol. 2001;126(2):135–139.
16. Von Baehr V, Hermes A, von Baehr R, et al. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine. J Investig Allergol Clin Immunol. 2005;15(4):234–241.
17. Fam SS, Morrow JD. The isoprostanes: unique products of arachidonic acid oxidation-a review. Curr Med Chem. 2003;10(17):1723–1740.
18. Morrow JD, Harris TM, Roberts LJ. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem. 1990;184(1): 1–10.
19. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol. 2001;280(6):L1067–L1082.
20. Montuschi P, Corradi M, Ciabattoni G, et al. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med. 1999;160(1):216–220.
21. Zanconato S, Carraro S, Corradi M, et al. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J Allergy Clin Immunol. 2004;113(2):257–263.
22. Carraro S, Cogo PE, Isak I, et al. EIA and GC/MS analysis of 8-isoprostane in EBC of children with problematic asthma. Eur Respir J. 2010;35(6):1364–1369.
23. Baraldi E, Carraro S, Alinovi R, et al. Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax. 2003;58(6):505–509.
24. Baraldi E, Ghiro L, Piovan V, et al. Increased exhaled 8-isoprostane in childhood asthma. Chest. 2003;124(1):25–31.
25. Mondino C, Ciabattoni G, Koch P, et al. Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in children. J Allergy Clin Immunol. 2004;114(4):761–667.
26. Battaglia S, den Hertog H, Timmers MC, et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax. 2005; 60(8):639–644.
27. Zhao JJ, Shimizu Y, Dobashi K, et al. The relationship between oxidative stress and acid stress in adult patients with mild asthma. J Investig Allergol Clin Immunol. 2008;18(1):41–45.
28. Hunt JF, Fang K, Malik R, et al. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med. 2000;161(3 Pt 1):694–699.
29. Antus B, Barta I, Kullmann T, et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and COPD: a longitudinal study. Am J Respir Crit Care Med. 2010;182(12):1492–1497.
30. Inci D, Altintas DU, Kendirli SG, et al. The effect of specif ic immunotherapy on exhaled breath condensate nitrite levels. Allergy. 2006;61(7):899–900.
31. Baldrick P, Richardson D, Wheeler AW. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine. 2001;20(5–6):737–743.
32. Rosewich M, Schulze J, Fischer von Weikersthal-Drachenberg KJ, Zielen S. Ultra-short course immunotherapy in children and adolescents during a 3-years post-marketing surveillance study. Pediatr Allergy Immunol. 2010;21(Pt 2):185–9.